Skip to main content

Table 2 Summary of CAR T cell results in diffuse large B cell lymphoma

From: New agents and regimens for diffuse large B cell lymphoma

Target Agent Study Study phase Number of DLBCL patients (treated) Dose ORR (%) CR (%) References
CD19 Axicabtagene ciloleucel ZUMA-1 (NCT02348216) 1/2 101 2.0 × 106 CAR T cells/kg 83 58 [13]
CD19 axicabtagene ciloleucel (in combination with atezolizumab) ZUMA-6 (NCT02926833) 1 12 2.0 × 106 CAR T cells/kg 90 60 [22]
CD19 tisagenlecleucel JULIET (NCT02445248) 2 93 0.1–6 × 108 CAR T cells 52 40 [12]
CD19 lisocabtagene maraleucel TRANSCEND NHL 001 (NCT02631044) 1 268 50–150 × 106 CAR T cells 73 53 [139]
CD19 CTL019 NCT02030834 2a 28 1.79–5.00 × 106 CAR T cells 64 43 [11]
CD19 ET019003 NCT04014894 1 6 2–3 × 106 CAR T cells/kg 100 [140]
CD19 FMC63-28Z NCT00924326 1/2 7 1–5 × 106 CAR T cells/kg 85 71 [141]
CD19/CD22 AUTO3 (in combination with pembrolizumab) ALEXANDER (NCT03287817) 1/2 24 50 × 106 CAR T cells 57 29 [21]
  1. DLBCL diffuse large B cell lymphoma, CAR chimeric antigen receptor, ORR overall response rate, CR complete response